Drug Trial Radar · NCT05208762
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
714
Planned (sponsor's estimate)
Start
Oct 25, 2022
Primary completion
Jan 5, 2028
Study completion Jan 4, 2029
Sponsor
- Lead sponsor
- Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have five parts. Parts A and B of the study will find out how much PF-08046054/SGN- PDL1V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe PF-08046054/SGN-PDL1V is and if it works to treat solid tumor cancers. In Part D and E, participants will be given PF-08046054/SGN-PDL1V with pembrolizumab to find out how safe this combination is and if it works to treat solid tumor cancers.
Conditions
- Carcinoma, Non-Small-Cell Lung
- Squamous Cell Carcinoma of the Head and Neck
- Esophageal Squamous Cell Carcinoma
- Triple Negative Breast Neoplasms
- Gastric Cancer
- Endometrial Cancer
- Pancreatic Adenocarcinoma
- Hepatocellular Carcinoma
Interventions
PF-08046054Drug
Given into the vein (IV; intravenously)
pembrolizumabDrug
200 mg once every 3 weeks given into the vein (IV; intravenously)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Through approximately 90 days after last study treatment; up to 3 years
- Number of participants with laboratory abnormalitiesTime frame: Through approximately 90 days after last study treatment; up to 3 years
- Number of participants with dose-limiting toxicities (DLTs)Time frame: Through the first cycle of study treatment; approximately 1 month
- Number of participants with DLTs by dose levelTime frame: Through the first cycle of study treatment; approximately 1 month
Locations
62 sites in 11 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
University of Alabama at Birmingham, IDS Pharmacy
Birmingham, Alabama · Recruiting
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
UC Irvine Health - Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
University of California, Davis Medical Center
Sacramento, California · Recruiting
University of Iowa
Iowa City, Iowa · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Karmanos Cancer Institute
Farmington Hills, Michigan · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
University of Texas Southwestern Medical Center - Simmons Cancer Center
Dallas, Texas · Recruiting
UT Southwestern Medical Center - Redbird
Dallas, Texas · Recruiting
Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital
Dallas, Texas · Recruiting
University of Texas Southwestern Medical Center - William P. Clements, Jr., University Hospital
Dallas, Texas · Recruiting
University Of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
UT Southwestern - Simmons Cancer Center - Fort Worth
Fort Worth, Texas · Recruiting
The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services
Houston, Texas · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
UT Southwestern - Simmons Cancer Center - Richardson/Plano
Richardson, Texas · Recruiting
NEXT Virginia, LLC
San Antonio, Texas · Recruiting
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Institut Jules Bordet
Anderlecht, Belgium · Recruiting
University Health Network
Toronto, Ontario, Canada · Recruiting
University Health Network, Princess Margaret Hospital
Toronto, Ontario, Canada · Recruiting
McGill University Health Centre
Montreal, Quebec, Canada · Recruiting
Beijing Friendship hospital, Capital Medical University
Beijing, China · Recruiting
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Hôpital Saint André - CHU Bordeaux
Bordeaux, France · Recruiting
Clinique Ambroise Pare
Neuilly-sur-Seine, France · Recruiting
Institut Curie
Paris, France · Recruiting
lnstitut Curie Pharmacy
Paris, France · Recruiting
Gustave Roussy Institute - Service pharmacie
Villejuif, France · Recruiting
Gustave Roussy Institute
Villejuif, France · Recruiting
Charite Comprehensive Cancer Center
Berlin, Germany · Recruiting
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.